Nothing Special   »   [go: up one dir, main page]

CO6541545A2 - Compuestos de espiropiperidina como antagonistas del receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas del receptor orl-1

Info

Publication number
CO6541545A2
CO6541545A2 CO12073055A CO12073055A CO6541545A2 CO 6541545 A2 CO6541545 A2 CO 6541545A2 CO 12073055 A CO12073055 A CO 12073055A CO 12073055 A CO12073055 A CO 12073055A CO 6541545 A2 CO6541545 A2 CO 6541545A2
Authority
CO
Colombia
Prior art keywords
orl
compounds
spyropiperidine
antrogonists
receiver
Prior art date
Application number
CO12073055A
Other languages
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Escribano Miguel Angel Toledo
Concepcion Pedregal-Tercero
Grau Maria Angeles Martinez
Blanco Celia Lafuente
Aguado Alma Maria Jimenz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6541545A2 publication Critical patent/CO6541545A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos derivados de espiropiperidina de la fórmula:Así corno a sus métodos de obtención, y composiciones farmacéuticas donde puedan estar presentes actuando como antagonistas del receptor ORL-1, las cuales tienen aplicación en el tratamiento de enfermedades mediadas por la actividad de dicho receptor, tales como: depresión, migraña y/o obesidad.
CO12073055A 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1 CO6541545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6541545A2 true CO6541545A2 (es) 2012-10-16

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12073055A CO6541545A2 (es) 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (es)
EP (1) EP2501703B1 (es)
JP (1) JP5680101B2 (es)
KR (1) KR101363830B1 (es)
CN (1) CN102612520B (es)
AR (1) AR078863A1 (es)
AU (1) AU2010319581C1 (es)
CA (1) CA2796161C (es)
CO (1) CO6541545A2 (es)
CR (1) CR20130087A (es)
DK (1) DK2501703T3 (es)
DO (1) DOP2012000135A (es)
EA (1) EA020848B1 (es)
EC (1) ECSP12011902A (es)
ES (1) ES2435814T3 (es)
HK (1) HK1169988A1 (es)
HN (1) HN2012001011A (es)
HR (1) HRP20130967T1 (es)
IL (1) IL219370A (es)
JO (1) JO2887B1 (es)
MA (1) MA33751B1 (es)
ME (1) ME01537B (es)
MX (1) MX2012005691A (es)
MY (1) MY160665A (es)
NZ (1) NZ600006A (es)
PE (1) PE20121430A1 (es)
PL (1) PL2501703T3 (es)
PT (1) PT2501703E (es)
RS (1) RS53018B (es)
SI (1) SI2501703T1 (es)
TW (1) TWI465453B (es)
UA (1) UA107943C2 (es)
WO (1) WO2011060035A1 (es)
ZA (1) ZA201202967B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
WO2012052540A1 (en) * 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
PT2903440T (pt) 2012-10-02 2017-12-18 Bayer Cropscience Ag Compostos heterocíclicos como pesticidas
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
AR105821A1 (es) 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
DK3589638T3 (da) 2017-03-02 2021-06-07 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-Gamma-T
CN110392688B (zh) * 2017-03-02 2021-09-10 伊莱利利公司 用于抑制ROR-γ-T的化合物
US10780074B2 (en) 2017-08-02 2020-09-22 Sunovion Pharmaceuticals Inc. Compounds and uses thereof
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
KR20210116483A (ko) 2018-12-17 2021-09-27 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 그의 사용 방법
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
AR123355A1 (es) 2020-08-26 2022-11-23 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
PL367263A1 (en) * 2001-04-18 2005-02-21 Euro-Celtique, S.A. Spiropyrazole compounds
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
DE60226874D1 (de) * 2001-07-23 2008-07-10 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
CA2466915A1 (en) * 2002-01-28 2003-08-07 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
WO2003095427A1 (fr) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Compose a noyau spiranique
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
CN100402529C (zh) * 2002-09-09 2008-07-16 詹森药业有限公司 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
MXPA06011265A (es) * 2004-03-29 2006-12-15 Pfizer Compuestos propanamida alfa aril o heteroaril metil beta piperidino como antagonistas del receptor orl1.
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
RU2497824C2 (ru) * 2008-03-27 2013-11-10 Грюненталь Гмбх Производные замещенного спироциклического циклогексана

Also Published As

Publication number Publication date
WO2011060035A1 (en) 2011-05-19
NZ600006A (en) 2014-05-30
JP5680101B2 (ja) 2015-03-04
KR101363830B1 (ko) 2014-02-14
HK1169988A1 (en) 2013-02-15
IL219370A (en) 2015-01-29
UA107943C2 (en) 2015-03-10
ECSP12011902A (es) 2012-07-31
HN2012001011A (es) 2015-08-31
DOP2012000135A (es) 2012-08-15
CA2796161C (en) 2015-03-17
PT2501703E (pt) 2013-11-26
MY160665A (en) 2017-03-15
CN102612520A (zh) 2012-07-25
US20110118251A1 (en) 2011-05-19
AU2010319581A1 (en) 2012-06-07
CA2796161A1 (en) 2011-05-19
MX2012005691A (es) 2012-06-13
DK2501703T3 (da) 2013-10-14
RS53018B (en) 2014-04-30
AU2010319581C1 (en) 2014-05-15
PL2501703T3 (pl) 2014-02-28
IL219370A0 (en) 2012-06-28
HRP20130967T1 (hr) 2013-11-22
JO2887B1 (en) 2015-03-15
KR20130026523A (ko) 2013-03-13
EA020848B1 (ru) 2015-02-27
US8232289B2 (en) 2012-07-31
PE20121430A1 (es) 2012-10-26
CR20130087A (es) 2013-04-17
CN102612520B (zh) 2015-04-08
SI2501703T1 (sl) 2013-11-29
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
ES2435814T3 (es) 2013-12-23
EA201290352A1 (ru) 2012-10-30
ME01537B (me) 2014-04-20
EP2501703A1 (en) 2012-09-26
JP2013510859A (ja) 2013-03-28
AU2010319581B2 (en) 2013-12-19
EP2501703B1 (en) 2013-09-18
TW201127841A (en) 2011-08-16
AR078863A1 (es) 2011-12-07
MA33751B1 (fr) 2012-11-01

Similar Documents

Publication Publication Date Title
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
GT200900231A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CR20110509A (es) Composicion farmaceutica
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
BR112012007747B8 (pt) compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
DK3061821T3 (da) Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering
GT201200201A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
UY32574A (es) Antagonistas del receptor cxcr3
UY33924A (es) Compuestos de triazolopiridina como inhibidores de cinasa pim
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CO6781501A2 (es) Dihidrofuranos condensados en calidad de modulares de gpr119 para el tratamiento de diabetes, obesidad y trastornos relacionados
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
EA201391618A1 (ru) Комбинация, содержащая умеклидиний и кортикостероид
CR11600A (es) Derivados de indazol
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep

Legal Events

Date Code Title Description
FG Application granted